Rebecca Silbermann, MD, MMS, outlines key trial design considerations in multiple myeloma, including supportive care measures and end point selection.
Rebecca Silbermann, MD, MMS
Advertisement
Articles by Rebecca Silbermann, MD, MMS
Rebecca Silbermann, MD, MMS, discusses the phase 3 CASTOR trial in relapsed/refractory multiple myeloma.
Rebecca Silbermann, MD, MMS, discusses the role of disease biology in multiple myeloma.
Rebecca Silbermann, MD, MMS, discusses current treatment options for fit patients with multiple myeloma who experience early relapse.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts Third RP1 BLA Resubmission With Nivolumab in Advanced Melanoma
2
Real-World Mogamulizumab Elicits Durable Responses in Pretreated Mycosis Fungoides and Sézary Syndrome
3
From "Not Curable" to "May Be Curable": Joshua Richter, MD, on the New Reality of Multiple Myeloma
4
MAIC Shows OS Benefit With Mogamulizumab vs Vorinostat in Cutaneous T-Cell Lymphoma Subtypes
5